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A	debate	about	the	market-leading	influenza	antiviral	medi-
cation,	oseltamivir,	which	 initially	 focused	on	treatment	 for	
generally	mild	 illness,	has	been	expanded	to	question	the	
wisdom	of	stockpiling	 for	use	 in	 future	 influenza	pandem-
ics.	Although	randomized	controlled	trial	evidence	confirms	
that	 oseltamivir	 will	 reduce	 symptom	 duration	 by	 17–25	
hours	among	otherwise	healthy	adolescents	and	adults	with	
community-managed	 disease,	 no	 randomized	 controlled	 
trials	have	examined	the	effectiveness	of	oseltamivir	against	
more	 serious	 outcomes.	 Observational	 studies,	 although	
criticized	on	methodologic	grounds,	suggest	that	oseltami-
vir	given	early	can	reduce	the	risk	for	death	by	half	among	
persons	 hospitalized	 with	 confirmed	 infection	 caused	 by	
influenza	A(H1N1)pdm09	 and	 influenza	A(H5N1)	 viruses.	
However,	 available	 randomized	 controlled	 trial	 data	 may	
not	be	able	to	capture	the	effect	of	oseltamivir	use	among	
hospitalized	 patients	with	 severe	 disease.	We	assert	 that	
data	on	outpatients	with	relatively	mild	disease	should	not	
form	the	basis	for	policies	on	the	management	of	more	se-
vere	disease.
A lively, and sometimes heated, debate has recently been conducted in the popular press (1) and medical litera-
ture (2–4) about the effectiveness of oseltamivir, its useful-
ness in treating seasonal influenza, and the need for it to 
be stockpiled for use in a future influenza pandemic. Osel-
tamivir, manufactured by F. Hoffmann-La Roche (Roche) 
(Indianapolis, IN, USA), is the market leader of the neur-
aminidase inhibitors (NAI), the first class of antiviral drugs 
designed specifically to treat influenza.
Oseltamivir came on the market in many countries in 
2000 after clinical studies had been conducted among in-
fluenza virus–infected patients with uncomplicated illness. 
Trial data from outpatient studies have been summarized 
in a recent meta-analysis of individual patient data, includ-
ing published and unpublished studies, which confirms 
that oseltamivir will reduce the duration of symptomatic 
laboratory-confirmed influenza in otherwise healthy adults 
from 5 days to 4 days (2), a result consistent with those of 
a previous systematic review by the Cochrane group (3).
After the drug’s market release, oseltamivir use for 
treatment of seasonal influenza was modest in most coun-
tries, except for Japan, where widespread use of the drug was 
adopted. However, governments began to consider antiviral 
drug administration as a key component of their planned pan-
demic response after human infections with avian influenza 
A(H5N1) virus increased in 2003 and were associated with 
a case-fatality risk of >50% (5). Suitable vaccines would not 
be available at the start of a pandemic; thus, use of antiviral 
agents was seen as a critical part of a pandemic response.
Because the mode of administration for oseltamivir 
was simpler (oral) than that for zanamivir (inhalation) and 
because the systemic effect of oseltamivir was expected to 
be appropriate for treatment of highly pathogenic virus-
es, oseltamivir was suddenly in high demand, apparently 
driven by warnings from Roche that preemptive stockpil-
ing was the only way that governments could be assured of 
drug availability (6). Since 2005, governments of middle-
income and high-income countries around the world have 
spent billions of dollars (estimated) stockpiling oseltamivir 
(7). However, by November 2015, the influenza A(H5N1) 
virus that initiated stockpiling had caused only 844 human 
cases of infection and 449 deaths (case-fatality risk 53.2%) 
across 16 countries worldwide, with only 7 countries re-
porting >10 cases (8).
The first pandemic of the 21st century occurred un-
expectedly in 2009 after the global spread of a novel vi-
rus—influenza A(H1N1)pdm09—of swine (rather than 
avian) origin. In response, many countries activated their 
stockpiles of antiviral agents or accessed existing commu-
nity supplies. This was the first time that specific antiviral 
drugs were available in a pandemic. In the United States 
during 2009, 8.7 million oseltamivir prescriptions (28.4 
prescriptions/1,000 persons) were dispensed from commu-
nity pharmacies, not from the stockpile, at a cost of US 
$905 million (9).
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Although the number of deaths due to the 2009 pan-
demic was lower than initially anticipated, a unique oppor-
tunity was provided to review the effectiveness of oselta-
mivir in the pandemic setting and to determine the benefit 
of oseltamivir for patients who were hospitalized with con-
firmed influenza A(H1N1)pdm09 virus infection. Such 
observational data were valuable to ascertain the effect of 
oseltamivir in severely ill or hospitalized patients given the 
continued absence of data from placebo-controlled, ran-
domized controlled trials.
Questioning whether oseltamivir is useful for treating 
serious illness and whether it should be stockpiled has ex-
tended the debate on the effectiveness of oseltamivir in the 
community. We believe that these issues should be consid-
ered separately.
Oseltamivir Treatment of Seasonal Influenza 
After partially successful efforts to retrieve unpublished 
data from Roche (10,11), the Cochrane group conducted 
a meta-analysis of the effectiveness of oseltamivir in treat-
ing uncomplicated community-acquired influenza. Their 
findings led the group to conclude that oseltamivir had no 
specific antiviral effect, even though the drug had been spe-
cifically designed to achieve exactly that (3). The Cochrane 
systematic review, which focused only on an intention-to-
treat analysis, confirmed that oseltamivir reduced symptom 
duration in the intention-to-treat group by <24 hours. Ear-
lier, the Cochrane group had noted, “We are unsure of the 
generalizability of our conclusions from seasonal to pan-
demic or avian influenza” (12).
As noted previously, a subsequent meta-analysis 
(funded by an unrestricted grant from Roche) also con-
firmed a ≈1-day reduction in symptoms among adults and 
adolescents who had laboratory-confirmed influenza and 
were treated within 48 hours of symptom onset (2). This 
analysis included outcomes of both intention-to-treat and 
intention-to-treat-infected groups. Benefit was found for 
the intention-to-treat-infected group, but no benefit was 
found for patients with influenza-like illness who did not 
have laboratory-confirmed influenza (the intention-to-treat 
but not infected group) (2). Given that the benefit of osel-
tamivir was confined to symptomatic patients with labo-
ratory-confirmed infection, the authors concluded that the 
effect of oseltamivir was due to its effect on the influenza 
virus, rather than a nonspecific antiviral effect, as had been 
suggested by the Cochrane group (3).
Secondary analyses from the Roche-sponsored meta-
analysis suggested the following: a 63% (95% CI 19%–
83%) decreased risk in hospitalization for any cause, based 
on 9/1,591 (0.6%) oseltamivir treated vs 22/1,302 (1.7%) 
placebo-treated patients; and a 44% (95% CI 25%–58%) 
decreased risk of antibiotic prescription for lower respirato-
ry disease in patients with laboratory-confirmed influenza, 
based on 65/1,544 (4.2%) oseltamivir-treated vs 110/1,263 
(8.7%) placebo-treated patients. However, hospital admis-
sions were all cause and not confined to those that may have 
been associated with influenza infection; also, no formal di-
agnostic criteria existed for lower respiratory tract infection 
(2,13). We consider these secondary analyses less convinc-
ing than the analyses of primary endpoints. The latter were 
largely in agreement with those of the Cochrane group. 
Yet, despite this agreement and the arm’s length funding 
mechanism, the Roche-sponsored meta-analysis has been 
criticized as being influenced by the manufacturer (14).
Oseltamivir Treatment of Severe Influenza 
Although necessary to consider oseltamivir’s effect on 
more serious infections, no randomized controlled trials 
exist that can be included in a meta-analysis. The Cochrane 
group chooses only to conduct meta-analyses of random-
ized controlled trials, which are generally accepted to be 
the highest level of evidence. Thus, the Cochrane group 
could not review severe outcomes of laboratory-confirmed 
influenza. Evidence is instead derived from observational 
studies on the use of oseltamivir to treat complications of 
influenza virus infection, as in hospitalized patients or in 
those who died. These studies are subject to uncontrolled 
bias. For instance, sicker patients may be more (or less) 
likely to be treated, thus attenuating (or exaggerating) the 
effect of the intervention. Also, a serious outcome may oc-
cur soon after the treatment was initiated in a severely ill 
patient, so that the treatment has not had a chance to suc-
ceed. Similarly, patients who receive early treatment are 
more likely to benefit from treatment than patients who 
receive late treatment. To minimize bias, researchers con-
ducting observational studies have attempted to adjust for 
time from disease onset to treatment and time from treat-
ment to outcome. Some observational studies have also 
adjusted for propensity to be treated as well as patient co-
existing conditions and disease severity, which may affect 
treatment decisions and outcomes.
Observational studies that enrolled adults have of-
ten used death as an outcome, given its ease of definition. 
However, many observational studies fail to control com-
pletely for potential biases, including time biases. Among 
studies that have attempted to control for these biases, a 
decreased risk for death after oseltamivir treatment has 
been reported, and early treatment appears to be critical 
(4,15,16). For instance, in a retrospective cohort study from 
Israel of 449 patients hospitalized with influenza A(H1N1)
pdm09 infection, all patients were treated with oseltamivir, 
and 189 (42%) were treated within 48 hours. This observa-
tional study controlled for propensity to treat and patient 
coexisting conditions and demonstrated the odds of death 
increased by 2.2 times (95% CI 1.4–3.5 times) if treatment 
was started late (>48 hours after symptom onset) (16).
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In an attempt to overcome the criticisms of design and 
analysis of the observational studies, Roche chose to fund 
a patient level meta-analysis of individual data from 78 dif-
ferent observational studies, which included >29,000 pa-
tients. By adjusting for time, propensity to treat, and patient 
coexisting conditions, and comparing the effect of treat-
ment with no treatment in patients infected with influenza 
A(H1N1)pdm09, researchers found that the odds of death 
were reported as 0.50 (95% CI 0.37–0.67) for adults whose 
treatment was initiated within 48 hours, compared with the 
odds of death for untreated adults (4). However, in a series 
of exchanges published in the British Medical Journal and 
The Lancet Respiratory Medicine, even this carefully de-
signed study has been criticized on methodologic grounds 
(17–20). A more recent meta-analysis of individual patient 
data from the same group of investigators examined the 
potential effect of oseltamivir on influenza-related pneu-
monia among >20,000 patients with laboratory-confirmed 
influenza A(H1N1)pdm09 (21). However, this study has 
many of the predictable methodologic problems associated 
with retrospective reviews and does not add to the evidence 
base. There is scant other evidence for the benefit of oselta-
mivir on reducing the risk for death to help resolve residual 
uncertainty. The few potentially informative observational 
studies report on human infection with avian influenza 
strains (22) and seasonal influenza (15,23), including an 
unpublished review sponsored by Roche (24,25).
In a review of individual patient data for 308 patients 
from observational studies conducted in 12 countries, 
based on data from a patient register funded by Roche, 
oseltamivir treatment was reported to decrease the risk 
for death from influenza A(H5N1) virus by 49% (95% CI 
23%–66%). The analysis of risk for death was restricted 
to 258 patients from 7 countries; mean values were substi-
tuted for missing data (22).
Two prospective observational studies of hospitalized 
patients with laboratory-confirmed seasonal influenza have 
shown oseltamivir treatment decreases the risk for death. In 
a prospective observational cohort study from Hong Kong, 
which enrolled 754, mostly elderly, hospitalized patients 
with co-existing conditions during 2007–2008, oseltamivir 
treatment was associated with a reduced risk for death (ad-
justed hazard ratio 0.27, 95% CI 0.13–0.55; p<0.001), with 
a further reduction associated with earlier treatment (15). 
A small prospective observational study of patients hospi-
talized with laboratory-confirmed influenza in the 2005–06 
season in Ontario, Canada, found the adjusted odds ratio of 
death among oseltamivir-treated patients was 0.21 (95% CI 
0.06–0.80; p = 0.03), based on 22 (10%) of 219 deaths in 
the untreated group compared with 4 of 103 deaths in the 
treated group (23).
Also supporting the conclusion that oseltamivir use 
has a beneficial effect on reducing the risk for death were 
findings from a large review from the Ingenix Research 
Data Mart (24), apparently sponsored by Roche. We have 
only been able to find an abstract of the study with an as-
sociated commentary (25). The observational study found 
that oseltamivir use decreased the risk for death in patients 
of all ages with influenza (1 death/39,202 patients) com-
pared with untreated patients (56 deaths/136,799 patients; 
p = 0.02). However, the commentary raised several issues 
related to study design, which could not be resolved with-
out further detail (25).
We have not been able to find an analysis of oseltami-
vir effectiveness for treating infections with avian influenza 
A(H7N9) virus in China, a virus that, since its emergence 
in 2013, has caused a greater number of annual cases and 
deaths than influenza A(H5N1) virus. Such a study might 
also contribute to the evidence base.
Oseltamivir Policies for Seasonal and  
Pandemic Influenza
The  evidence from randomized controlled trials is clear 
that oseltamivir treatment decreases the duration of symp-
toms by up to 1 day in adolescent and adult patients with 
laboratory-confirmed seasonal influenza whose infections 
are able to be managed in the community. Oseltamivir 
provides no benefit to patients who have influenza-like ill-
ness not caused by influenza virus (2). Reviews of obser-
vational data regarding patients hospitalized with influenza 
A(H1N1)pdm09 or influenza A(H5N1) infections found 
that risk for death is cut in half if treatment is initiated 
within 48 hours of symptom onset (4,22). Small prepan-
demic observational studies, although they generally have 
controlled less for potential biases, also support the conclu-
sion that risk for death is decreased with oseltamivir treat-
ment (15,23).
These 2 lines of evidence may appear inconsistent. 
How would an intervention that has a modest effect on 
symptom duration in patients whose uncomplicated in-
fluenza was treated after a visit to a general practitioner 
be able to cut in half the risk for death among hospital-
ized patients?
It should not be surprising that treatment for uncompli-
cated influenza will only produce a modest effect because 
influenza virus replication precedes symptoms by 1–2 
days. This means that the viral load in the patient may have 
peaked by the time the patient begins antiviral treatment. 
Given that most antiviral drugs, including oseltamivir, act 
by reducing viral replication, the effect of treatment will 
therefore be minimal in otherwise healthy persons when 
immune responses are already reducing viral titers. It is 
therefore plausible that community-based randomized con-
trolled trials are not capturing critical information about the 
mode of action of oseltamivir that is beneficial to severely 
ill patients.
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It is possible that benefit to severely ill patients may 
be related to the increased duration of viral shedding and 
higher viral loads found in this group of patients (26). El-
evated cytokine levels, sometimes referred to as a cytokine 
storm, have been detected for patients infected with highly 
pathogenic A(H5N1) virus (27) and for severely ill patients 
infected with influenza A(H1N1)pdm09 and seasonal in-
fluenza viruses (28,29). A randomized controlled trial 
study of 117 healthy adults experimentally infected with 
seasonal influenza virus A(H1N1) reported that oseltamivir 
treatment significantly reduced interleukin-6, interferon-γ, 
and tumor necrosis factor-α cytokine responses in patients 
compared with responses in placebo-treated patients (30). 
Although these results do not clarify whether the decreased 
cytokine response was the result of effective viral treatment 
or a (postulated) immune modulatory effect of oseltamivir, 
ferret studies conducted in our laboratory suggest that os-
eltamivir treatment consistently reduces peak temperatures 
and improves ferret activity/wellness but often does so in 
the absence of any significant effect on viral load (31). The 
difference in outcome for severely infected patients treated 
with oseltamivir may relate to decreasing the adverse out-
come associated with a cytokine storm, which would not be 
expected in patients with mild disease.
Implications for Stockpiling
Data from the randomized controlled trials of patients with 
mild influenza and the observational data from severely ill 
patients demonstrate the clear clinical benefits of initiating 
treatment as early as possible after infection (32). NAI use 
in Japan is so widespread that almost every confirmed in-
fluenza case is treated, which is likely to have led to the 
extensive and rapid delivery of the drugs in the 2009 pan-
demic. For instance, in a study of Japanese children hos-
pitalized with influenza A(H1N1)pdm09 virus infections, 
>98% (984/1,000) were treated with an NAI, and for those 
for whom the treatment time was recorded, 89% received 
NAIs within 48 hours and 70% within 24 hours. Only 1% 
of the hospitalized children ultimately required mechanical 
ventilation, and 1 death was recorded (33).
Similar ecologic data were observed among pregnant 
women in Japan, a group of patients at increased risk for 
hospitalization and death when infected with influenza 
A(H1N1)pdm09. Pregnant Japanese women were treated 
prophylactically after close contact with an infected per-
son, and if infected and hospitalized, >90% were given 
NAIs within 48 hours of symptom onset. In comparison to 
the high mortality rates among pregnant women in many 
countries around the world (34), no maternal deaths oc-
curred in Japan during the pandemic (35).
Ecologic data from Japan, although regarded as the 
weakest form of epidemiologic evidence, suggest that rapid 
access to stockpiled NAIs in a pandemic is necessary to 
achieve the greatest benefit from their use. Rapid access 
during the 2009 pandemic in Japan was possible because 
rapid access represented routine care for seasonal influen-
za. In other countries, the 2009 pandemic confirmed that 
centralized stockpiles did not facilitate rapid distribution 
(36) and that decentralized stockpiles would be more effi-
cient. Stockpiles in hospitals, for example, would facilitate 
rapid treatment of ill patients in a pandemic but might also 
allow the periodic use of some material for the treatment of 
interpandemic seasonal influenza to avoid wastage due to 
an expiring stockpile (36).
The Way Forward
There is general agreement derived from randomized con-
trolled trials about the modest effectiveness of oseltamivir 
against relatively mild illness in otherwise healthy persons, 
but several lines of evidence from observational studies 
suggest that oseltamivir decreases the risk for death (37). 
However, within the next 5–10 years, we do not expect to 
see clarifying new evidence from trials of patients recruited 
from the community who have an endpoint of severe influ-
enza. Severe outcomes from influenza are uncommon, as 
shown in the meta-analyses of community trial data, and 
randomized controlled trials that recruit healthy persons 
would require extremely large patient numbers and need 
to be conducted over multiple seasons to account for po-
tentially different outcomes by influenza type and sub-type.
On the other hand, a randomized controlled trial that 
recruited only patients with severe influenza, although fea-
sible from a design perspective, could not ethically evalu-
ate active treatment versus placebo treatment because os-
eltamivir treatment is the standard of care for patients with 
severe influenza virus infections. In a study that overcame 
the ethical issue, a randomized controlled trial of patients 
with severe influenza that examined single-dose versus 
double-dose oseltamivir found no difference in outcomes 
between the 2 treatment arms (38). We do not anticipate 
that this trial would be repeated.
Existing observational evidence on the benefits of osel-
tamivir for the treatment of influenza in hospitalized patients, 
including assessing the risk for death, accrues from ecologic 
data from Japan, weak secondary analyses from randomized 
controlled trials of laboratory-confirmed influenza initially 
managed in the community, and the systematic reviews and 
analyses of observational studies of patients with confirmed 
infections caused by influenza A(H1N1)pdm09 and influ-
enza A(H5N1) viruses. Methodologically less robust, small 
observational studies conducted before the pandemic support 
the finding that oseltamivir decreases the risk for death. How-
ever, well-designed prospective observational studies may 
provide the most informative data in the next 5–10 years.
We reached several conclusions regarding the use of 
oseltamivir and the considerations that will be necessary 
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for future studies (Table). Nguyen-Van-Tam et al. recently 
outlined a list of covariates that would need to be collected 
to help strengthen the evidence that oseltamivir treatment 
benefits hospitalized patients with influenza (39). These in-
clude standardized data on illness onset and progression, 
comorbid conditions, disease severity, treatment, duration 
of hospital stay, the need for critical care, and influenza-
related mortality. In addition, a review by the UK Academy 
of Medical Sciences, sponsored by the Wellcome Trust, 
has offered a range of approaches to potential future studies 
and called specifically for “pragmatic or adaptive [random-
ized controlled trial] designs” of neuraminidase inhibitors 
in hospitalized patients (37). Our conclusions are in broad 
agreement with those of this report.
The details of study design may be best accomplished 
by an experienced group of international researchers, fo-
cusing on standardized recruitment procedures and covari-
ate and outcome definitions with a clearly defined analysis 
plan designed to minimize bias, as far as possible. Funding 
for such studies could come from the public or private sec-
tors, with prior safeguards on perceptions of conflicts of 
interest. The studies should be adaptable to evaluate new 
antiviral medications, including intravenous forms of the 
NAIs, newly licensed non-NAI antiviral agents that are 
currently in late-phase clinical trials, or adjunctive thera-
pies and immunomodulatory agents. Combinations of nov-
el drugs with existing NAIs will likely be a useful approach 
and will require evaluation. Plans for ensuring broad avail-
ability and regulatory approval for emergency use of unli-
censed antiviral agents will need to be established on very 
short notice. If pragmatic trials or high-quality prospective 
observational studies are completed and published over the 
next decade, an improved evidence base may help clini-
cians and public health planners decide on the most appro-
priate use of oseltamivir and potential new influenza anti-
viral agents for patients with severe infections caused by 
seasonal or pandemic influenza.
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Table. Conclusions	of	study	evaluating	the	use	of	oseltamivir	for	
seasonal	and	pandemic	influenza	and	wisdom	of	stockpiling* 
Summary	conclusions 
1.	Although	debate	continues,	there	is	general	agreement	from	
meta-analyses	of	RCTs	that	oseltamivir	reduces	symptoms	in	
healthy	adults	and	adolescents	with	influenza	by	up	to	1 day.	
There	is	disagreement	on	the	mechanism.	On	1 side	of	the	
debate,	the	Cochrane	group	maintains	that	there	is	a	nonspecific	
effect	of	oseltamivir, whereas,	on	the	other	side,	investigators	
sponsored	by	Roche	maintain	that	oseltamivir	has a	specific	
anti–influenza	virus	effect. 
2.	There	have	been no	RCTs	that	can	be	meta-analyzed to 
summarize	the	effect	of	oseltamivir	on	severe	outcomes	of	
influenza	virus	infection.	Evidence	derived	from	observational	
studies	of	serious	outcomes	consistently	suggests	that	
oseltamivir	reduces	the	risk	for	death in	severely	ill	patients	with	
documented	influenza	infection. 
3.	The	apparent	discrepancy	between	a	modest	drug	effect	for	
healthy	persons and	a	substantial	effect	on	number	of	deaths 
remains	unexplained. Currently,	oseltamivir	is	the	only	licensed	
drug	available	for	all	ages.		 
4.	Based	on	available	evidence,	oseltamivir	should	be	used	for	
treatment	of	hospitalized	patients	with	laboratory-confirmed	
seasonal	influenza	and	stockpiled	for	the	treatment	of	patients	
with	severe	laboratory-confirmed	pandemic	influenza,	whether	
hospitalized	or	not.	These	stockpiles	should	be	widely	distributed	
to	facilitate	rapid	use	when	needed. 
5.	Without	a	mechanism	for	rapid	distribution	of	the	drug	in	an	
emergency,	any	potential	benefit	of	such	large-scale	stockpiling	
will	not	be	realized.	Rapid	distribution	in	an	emergency	is	only	
likely	if	a	mechanism	exists	for	routine rapid	distribution.	In	
countries	where	such	a	mechanism	does not exist,	we	see	no	
place	for	stockpiling	oseltamivir	for	widespread community	use	
during	a	pandemic.		 
6.	It	is	unlikely	that	conventional	RCT-level	evidence	to	support	
antiviral	treatment	of	severe	laboratory-confirmed	influenza	in	
hospitalized	patients	will	appear	within	the	next	decade	due	to	
the	ethical	constraints	of	evaluating	oseltamivir	vs	placebo,	when	
oseltamivir	is	the	current	standard	of	care	for	the	treatment	of	
severe	influenza	infection.	New	studies	should	be	pragmatic	trials	
or	high-quality	prospective	multisite	observational	studies	and	
employ	methods	to	minimize	bias	to	the	greatest	extent	possible. 
7.	Studies	designed	for	assessing	interventions	for	seasonal	
influenza	should	be	readily	adaptable	to	studies	of	pandemic	
influenza	on	very	short	notice.	Because of the	ethical	and	design	
constraints	of	RCTs,	prospective	observational	studies	are	more	
feasible	than	RCTs	in	an	emergency	response	situation.	In	
addition	to	data	on	outcome,	such	as	risk	of	ICU	admission	and	
death	among adults,	or	length	of	stay	among children,	these	
observational	studies	should	also	record	time	from	disease	onset	
to	treatment	and	time	from	treatment	to	outcome	to	minimize	
bias.	Sequential	data	on	markers	of	immune	function	in	at	least	a	
subset	of	recruited	patients	would	also	be	valuable. 
*RCT,	randomized	controlled	trial;	ICU,	intensive	care	unit. 
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